Table 2 Propensity score adjusted multivariable regression of outcomes by aortic valve replacement versus medical management for cancer and non-cancer patients^a

Age by 10 years

TAVR vs MM

TAVR vs SAVR

TAVR vs MM

TAVR vs SAVR

TAVR vs MM

TAVR vs SAVR

Non-white race

1.01 (1.01–1.01)

1.00 (1.00–1.01)

−43.90 (−47.04- -40.76)

−3.66 (− 192.18–184.84)

− 0.02 (− 0.02- -0.02)

−0.06 (− 0.07- -0.05)

Zip code income

1.03 (1.02–1.04)

0.98 (0.78–1.23)

3953.27 (3833.21-4073.34)

31,486.94 (25,653.33-37,320.55)

0.31 (0.30–0.32)

1.12 (0.84–1.40)

1st quartile

Reference

Reference

Reference

Reference

Reference

Reference

2nd quartile

0.96 (0.95–0.98)

0.91 (0.71–1.16)

2120.83 (1976.57-2265.09)

4416.36 (− 1564.70-10,397.41)

− 0.13 (− 0.15- -0.12)

−0.20 (− 0.49–0.09)

3rd quartile

0.92 (0.90–0.93)

0.98 (0.77–1.25)

5372.67 (5224.71-5520.64)

16,506.95 (10,558.02-22,455.89)

−0.17 (− 0.18- -0.16)

−0.49 (− 0.78- -0.20)

4th quartile

0.93 (0.91–0.95)

0.92 (0.71–1.19)

9909.08 (9751.90-10,066.26)

31,220.53 (25,154.54-37,246.52)

−0.11 (− 0.12- -0.09)

−0.25 (− 0.54–0.04)

Procedure

0.52 (0.43–0.63)

0.90 (0.70–1.16)

164,413 (162,704.90-166,121.10)

52,098.41 (46,359.88-57,836.93)

−0.01 (− 0.17–0.14)

− 3.85 (− 4.13- -3.58)

Malignancy

1.08 (1.06–1.10)

1.07 (0.78–1.47)

2606.99 (2441.96-2772.02)

− 7911.60 (− 15,835.76–12.55)

0.06 (0.05–0.08)

− 0.89 (− 1.27- -0.51)

Metastases

1.95 (1.91–2.00)

0.63 (0.15–2.70)

− 6706.27 (− 7033.93- -6378.60)

922.71 (− 575.25–22,025.82)

− 0.31 (− 0.34- -0.28)

0.86 (− 0.81–2.54)

With Procedure

0.71 (0.45–1.11)

0.76 (0.43–1.32)

−5186.04 (− 8627.01- -1745.08)

10,725.28 (− 575.25–22,025.82)

− 0.72 (− 1.04- -0.40)

0.35 (− 0.20–0.89)

Mortality risk by DRG

7.88 (7.81–7.96)

10.74 (8.93–12.93)

8108.62 (8042.55-8174.68)

21,602.97 (18,898.19-24,307.74)

2.10 (2.09–2.10)

4.29 (4.18–4.41)

Length of stay, days

7514.37 (7505.36-7523.38)

14,544.34 (14,262.47-14,826.21)